Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PRF1 | P14222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278904 | 0.97 | DPP4 (0.65) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL16140264 | 0.93 | DPP4 (0.62) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL50461 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL12180779 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL8577882 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL61713 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL2591087 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL10020287 | 0.87 | DPP4 (0.56) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL10472980 | 0.85 | APP (0.73) | DPP4APPCYP2A6CYP2E1CYP3A4 | |
| SCHEMBL16142361 | 0.85 | DPP4 (0.55) | DPP4APPCYP2A6CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114853-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| EP-3036305-B1 | COMPOUNDS WITH TERMINAL HETEROARYLCYANOVINYLENE GROUPS AND THEIR USE IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9917260-B2 | Compounds with terminal heteroarylcyanovinylene groups and their use in organic solar cells | BASF SE (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20160248021-A1 | COMPOUNDS WITH TERMINAL HETEROARYLCYANOVINYLENE GROUPS AND THEIR USE IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| WO-2015024848-A1 | COMPOUNDS WITH TERMINAL HETEROARYLCYANOVINYLENE GROUPS AND THEIR USE IN ORGANIC SOLAR CELLS | BASF SE (DE) | 2015-02-26 | — | — | WO | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| EP-1589788-B1 | CHARGE-TRANSPORTING VARNISH | NISSAN CHEMICAL IND LTD (JP) | 2014-07-09 | — | — | EP | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062384-A2 | REDUCED FLUENCE RATE PDT | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062385-A2 | METHOD TO PREVENT VISION LOSS | QLT, INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| US-5753692-A | PLANT EXTRACTS, IMMUNOSTIMULANTS TREATING IMMUNODEFICIENCY DISEASES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-19 | — | — | US | disclosed |
| US-5747525-A | ANTITUMOR AGENTS OF OLIGOMERS OF THIOPHENE | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-05 | — | — | US | disclosed |
| US-5602170-A | ADMINISTERING ANTIIFLAMMATORY AGENT | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | DPP4 1952/4885APP 3602/4885CYP2A6 284/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | DPP4 2865/4885APP 3183/4885CYP2A6 1221/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | DPP4 1489/4885APP 2147/4885CYP2A6 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.